CMV疫苗开发在第三阶段试验后停止, 试验显示它无法防止女性感染。 Moderna halted its CMV vaccine development after a Phase 3 trial showed it didn’t prevent infection in women.

Moderna 已停止开发用于预防先天性巨细胞病毒的 mRNA-1647 巨细胞病毒疫苗，此前一项 3 期试验显示它未能实现预防 16 至 40 岁血清阴性女性感染的主要目标，有效性在 6% 至 23% 之间。 Moderna has discontinued development of its mRNA-1647 cytomegalovirus vaccine for preventing congenital CMV after a Phase 3 trial showed it failed to meet its primary goal of preventing infection in seronegative women aged 16 to 40, with efficacy ranging from 6% to 23%. 这次审判涉及13个国家的约7 500名妇女。 The trial involved about 7,500 women across 13 countries. 虽然疫苗接种得很好,没有新的安全顾虑,但现代疫苗将继续对骨髓移植病人进行第二阶段试验。 While the vaccine was well-tolerated with no new safety concerns, Moderna will continue a Phase 2 trial in bone marrow transplant patients. 其结果不会影响2025年的财政指导或2028年的收支平衡预测, 并将与科学界分享全部数据。 The outcome won’t affect its 2025 financial guidance or breakeven projection by 2028, and full data will be shared with the scientific community.